Lantheus Holding - LNTH STOCK NEWS

Lantheus Holdings (NASDAQ: LNTH) has completed its acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, as announced on January 28, 2025. The acquisition brings key assets to Lantheus including:

• OCTEVY™, a registrational-stage PET diagnostic imaging agent for neuroendocrine tumors, complementing Lantheus' therapeutic candidate PNT2003
• A portfolio of clinical and pre-clinical theranostic pairs
• Radioligand therapy manufacturing infrastructure
• A revenue-generating CDMO business

The strategic move strengthens Lantheus' position in the radiopharmaceutical sector by expanding its capabilities across development, manufacturing, and commercialization.

Lantheus Holdings (NASDAQ: LNTH) reported strong financial results for Q4 and full year 2024. The company achieved worldwide revenue of $391.1M in Q4 (+10.5% YoY) and $1.53B for full year 2024. PYLARIFY reached blockbuster status with over $1B in net sales, while Q4 sales grew 15.7% to $266.0M.

Q4 highlights include DEFINITY sales increase of 17.9% to $86.2M, operating income decrease of 17.2% to $113.9M, and adjusted EPS decline of 9% to $1.59. The company's cash position strengthened to $912.8M by year-end 2024.

Lantheus announced strategic acquisitions including Life Molecular Imaging and Evergreen Theragnostics, expected to close in H2 2025. These deals aim to expand the company's radiopharmaceutical portfolio and manufacturing capabilities. The company also initiated a $250M share repurchase program, with $100M already executed at an average price of $89.59.

Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, has announced its participation in three major upcoming investor conferences in February and March 2025. The company's management team will present at:

• B. Riley Securities Precision Oncology & Radiopharma Day in New York (February 28)
• TD Cowen 45th Annual Health Care Conference in Boston (March 4, 2:30 PM ET)
• Leerink Global Healthcare Conference 2025 in Miami (March 11, 1:40 PM ET)

Live webcasts will be available for the TD Cowen and Leerink conferences through the Investors section of Lantheus's website. Replay access will be maintained for at least 30 days following the presentations.

Lantheus Holdings (NASDAQ: LNTH) has announced it will host a conference call and webcast to discuss its Q4 and full year 2024 financial results on Wednesday, February 26, 2025, at 8:00 a.m. ET.

Participants are encouraged to register fifteen minutes before the scheduled start time through the company's investor relations website to avoid delays. A replay of the webcast will be available approximately two hours after the event and will remain accessible for at least 30 days on the same web page.

Lantheus Holdings (NASDAQ: LNTH) has announced upcoming presentations of piflufolastat F 18 (PYLARIFY) data at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. Two key presentations will showcase PYLARIFY's capabilities: one focusing on early detection of recurrent prostate cancer in patients with minimal PSA levels, and another examining PYLARIFY's role in newly-diagnosed and recurrent prostate cancer patients based on registry data.

The presentations are scheduled for February 13, 2025, during Poster Session A, with studies from the University of California's Department of Radiation Oncology and Carolina Urologic Research Center. The research highlights PYLARIFY's effectiveness in real-world applications and its ability to detect prostate cancer recurrence in low PSA cases.

Lantheus Holdings (NASDAQ: LNTH) has appointed Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025. Dr. Morrow, currently Head of the Oncology Therapeutic Area Unit at Takeda, brings extensive expertise in clinical development and oncology therapeutics. She will serve as a member of the Board's Science and Technology Committee.

This appointment marks the second new board addition in five months, bringing the total number of directors to eleven, with nine being independent. Dr. Morrow's previous roles include Chief Medical Officer at CRISPR Therapeutics and Vice President at Amgen, where she led global therapeutic areas in oncology and related fields. She holds an M.D. from the University of Texas Medical School at Houston and completed specialized training at prestigious institutions.

Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to acquire Evergreen Theragnostics for an upfront payment of $250 million, with potential additional milestone payments of up to $752.5 million. The acquisition aims to transform Lantheus into a fully integrated radiopharmaceutical company.

The deal brings significant strategic advantages, including enhanced manufacturing infrastructure, a revenue-generating CDMO business, and the addition of OCTEVY™, a registrational-stage diagnostic agent for neuroendocrine tumors that complements Lantheus' PNT2003 therapeutic candidate. The acquisition also expands Lantheus' oncology pipeline with multiple clinical and pre-clinical theranostic pairs.

The transaction is expected to close in the second half of 2025, subject to customary conditions and regulatory clearances. Lantheus has reaffirmed its FY 2024 guidance with revenue of $1.51-1.52 billion and adjusted fully diluted EPS of $6.65-6.70.

Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to acquire Evergreen Theragnostics for an upfront payment of $250 million, with potential additional milestone payments of up to $752.5 million. The acquisition aims to transform Lantheus into a fully integrated radiopharmaceutical company.

The deal brings significant strategic advantages, including Evergreen's scalable manufacturing infrastructure, CDMO services, and OCTEVY™, a registrational-stage diagnostic agent for neuroendocrine tumors that complements Lantheus' therapeutic candidate PNT2003. The acquisition also expands Lantheus' oncology pipeline with multiple clinical and pre-clinical theranostic pairs.

The transaction is expected to close in the second half of 2025, subject to customary conditions. Lantheus has reaffirmed its FY 2024 guidance with revenue of $1.51-1.52 billion and adjusted fully diluted EPS of $6.65-6.70.

Lantheus Holdings (NASDAQ: LNTH) has announced a $250 million share repurchase program to be executed over the next twelve months. The company plans to begin repurchases in Q4 2023 through open market transactions, private negotiations, and other legal means, with timing and amounts determined by management based on market conditions. The program demonstrates the board's confidence in Lantheus' leadership in radiopharmaceuticals and growth potential. The company aims to balance capital return to shareholders while pursuing business development opportunities to expand its radiopharmaceutical portfolio.